Non-Small Cell Lung Cancer
The Non-Small Cell Lung Cancer pipeline: 587 tracked drugs, 60 approved for this indication.
60 approved / phase 4105 Phase 311 Phase 2/382 Phase 2132 Phase 1/2138 Phase 159 preclinical / unstaged
Compare the share prices of listed companies in Non-Small Cell Lung Cancer →
Total attributable cost
$12.5B
$70,896/patient
Drug spend
Not yet sourced
All stages, newly diagnosed (2026 incidence estimate) · US
The Non-Small Cell Lung Cancer pipeline
Key trial results for every approved and late-stage drug: Non-Small Cell Lung Cancer results by drug.